Review
Immunology
Wei-Jian Mei, Mi Mi, Jing Qian, Nan Xiao, Ying Yuan, Pei-Rong Ding
Summary: Colorectal cancers with high microsatellite instability and deficient mismatch repair have different characteristics compared to normal CRC, but the testing rates for MSI and MMR remain low in clinical practice. Insufficient testing fails to identify patients with these types of CRC who could benefit from immunotherapy. Understanding the importance of MMR/MSI status in the clinical characteristics and prognosis of CRC may help improve testing rates and guide the development of more effective therapies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yousun Chung, Soo Kyung Nam, Ho Eun Chang, Cheol Lee, Gyeong Hoon Kang, Hye Seung Lee, Kyoung Un Park
Summary: The study evaluated an experimental eight marker-panel for accurate determination of microsatellite instability (MSI) status in cancer patients. The testing showed high concordance with IHC analysis, with LMR markers demonstrating higher sensitivity and larger shifts compared to conventional markers in gastric and endometrial cancers. Further validation with larger sample sizes is needed for these LMR markers.
Article
Oncology
Pascale Palassin, Marion Lapierre, Samuel Pyrdziak, Antoine Wagner, Regine Stehle, Carole Corsini, Jacqueline Duffour, Sandrine Bonnet, Abdelhay Boulahtouf, Carmen Rodriguez, Alexandre Ho-Pun-Cheung, Evelyne Lopez-Crapez, Florence Boissiere-Michot, Frederic Bibeau, Simon Thezenas, Nabila Elarouci, Janick Selves, Jean-Sebastien Hoffmann, Paul Roepman, Thibault Mazard, Olivier Buhard, Alex Duval, Stephan Jalaguier, Vincent Cavailles, Audrey Castet-Nicolas
Summary: Microsatellite instability (MSI) is closely related to alterations in mismatch repair (MMR) genes and is important in the pathogenesis of colorectal cancer (CRC). The transcription factor NRIP1 is involved in intestinal tumorigenesis and can induce the transcription of MMR genes MSH2 and MSH6, reducing MSI and potentially affecting patient survival outcomes in CRC. A dominant-negative truncated mutant of NRIP1 may amplify MMR deficiency and play a role in advanced MSI CRC progression and prognosis.
Review
Oncology
Zhenli Diao, Yanxi Han, Yuqing Chen, Rui Zhang, Jinming Li
Summary: MSI is a valuable tool for identifying cancer patients who may benefit from immunotherapy, and is commonly detected through immunohistochemical methods and PCR amplification of microsatellite repeats. Next-generation sequencing and circulating tumor DNA offer promising alternatives for MSI detection when tumor tissue is not available. Additionally, MSI detection serves as an effective tool for screening Lynch syndrome and predicting outcomes and treatment responses for colorectal cancer patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Sofia Edin, Bjorn Gylling, Xingru Li, Asa Stenberg, Anna Lofgren-Burstrom, Carl Zingmark, Bethany van Guelpen, Ingrid Ljuslinder, Agnes Ling, Richard Palmqvist
Summary: This study investigates the tumor immune cell infiltration in relation to well-established molecular markers of colorectal cancer (CRC). The results show an association between higher immune cell infiltration and microsatellite instability, and opposite relationships of BRAF and KRAS mutations with tumor infiltration of cytotoxic T cells. The positive prognostic importance of cytotoxic T cells is found in wild-type as well as KRAS and BRAF-mutated CRCs in both cohorts.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Kjersti Elvestad Hestetun, Nina Benedikte Rosenlund, Luka Stanisavljevic, Olav Dahl, Mette Pernille Myklebust
Summary: Deficient mismatch repair (dMMR) is associated with improved prognosis in stage II colon cancer but not in stage III colon cancer.
FRONTIERS IN ONCOLOGY
(2022)
Editorial Material
Cell Biology
Gayathri Anandappa, Michael J. Overman
Summary: In a recent study, Amodio and colleagues discovered a method to modulate immunosurveillance in colorectal tumors by manipulating DNA mismatch repair heterogeneity. They found that enriching the MMR deficient component using 6-thioguanine can improve tumor control in murine models.
CELL REPORTS MEDICINE
(2023)
Article
Oncology
Giacomo Mazzoli, Romain Cohen, Sara Lonardi, Francesca Corti, Elena Elez, Marwan Fakih, Priya Jayachandran, Raphael Colle, Aakash Tushar Shah, Massimiliano Salati, Elisabetta Fenocchio, Lisa Salvatore, Margherita Ambrosini, Javier Ros, Rossana Intini, Chiara Cremolini, Michael J. Overman, Thierry Andre, Filippo Pietrantonio
Summary: The evaluation of clinical variables, including performance status (PS), is important in treatment decision-making for patients with dMMR/MSI-H mCRC.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Dong-Xiao Bai, Jian-an Xiao, Tian -Chen Huang, Zhi-Ling Shen, Lei Li, Fei-Fei Ding, Ming Wen, Shou-Xin Wu, Xiao-Chen Liu, Hui-Hui Jiang
Summary: This study aimed to explore the correlation between KRAS mutations/MSI status and serum trace elements (TEs) levels in patients with colorectal cancer (CRC). The serum concentrations of 18 TEs were detected and the correlations among KRAS mutations/MSI status, demographic and clinical characteristics, and TEs were analyzed. The results showed that CRC patients with different molecular subtypes presented different alterations in types and levels of serum TEs.
Article
Medicine, General & Internal
Shen-Yi Lian, Lu-Xin Tan, Xin-Zhi Liu, Lu-Jing Yang, Ning-Ning Li, Qing Feng, Ping Wang, Yue Wang, Dong-Bo Qiao, Li-Xin Zhou, Ting-Ting Sun, Lin Wang, Ai-Wen Wu, Zhong-Wu Li
Summary: This study assessed the clinicopathological features and prognostic values of KRAS, NRAS, BRAF, and DNA mismatch repair status in colorectal cancer (CRC) in developing countries. The mutation frequencies of KRAS, NRAS, and BRAF were 41.7%, 1.6%, and 3.8%, respectively. KRAS mutations and deficient mismatch repair (dMMR) status were associated with aggressive biological behaviors and poor differentiation, while BRAF (V600E) mutations were associated with well-differentiated tumors. The dMMR status predicted longer overall survival in all CRC patients.
Article
Oncology
Elaine Tan, Junmin Whiting, Hao Xie, Iman Imanirad, Estrella Carballido, Seth Felder, Jessica Frakes, Quanxing Mo, Christine Walko, Jennifer B. Permuth, Katelyn Sommerer, Richard Kim, Daniel A. Anaya, Jason B. Fleming, Ibrahim Halil Sahin
Summary: This study retrospectively analyzed a cohort of patients with MMR-D/MSI-H mCRC and identified BRAF mutations and age >50 as prognostic factors associated with worse survival outcomes, while RAS mutations and specific MMR alterations are not predictive of survival outcomes.
Article
Biochemistry & Molecular Biology
Vitaly Shubin, Yury Shelygin, Sergey Achkasov, Oleg Sushkov, Ilya Nazarov, Alexey Ponomarenko, Iuliia Alimova, Anna Loginova, Aleksey Tsukanov
Summary: The aim of this study was to determine the characteristics of Russian patients with microsatellite instability (MSI) tumors. The results showed that patients with MSI tumors differed in the age of diagnosis, tumor localization, time of cancer recurrence, and stage of the disease. Patients whose tumors had MSI status had higher overall and disease-free survival rates.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Emre Kucukkose, Matthijs J. D. Baars, Mojtaba Amini, Suzanna J. Schraa, Evelien Floor, Guus M. Bol, Inne H. M. Borel Rinkes, Jeanine M. L. Roodhart, Miriam Koopman, Jamila Laoukili, Onno Kranenburg, Yvonne Vercoulen
Summary: The study suggests that the distinct localization of CD8(+) T cells within the stroma in primary MSI-H CRC tumors may be associated with metastasis formation. Tumors with metastatic capacity exhibit high stromal content and low influx of CD8(+) T cells.
BRITISH JOURNAL OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Petri Rantanen, Anne Keranen, Shabane Barot, Sam Ghazi, Annelie Liljegren, Caroline Nordenvall, Annika Lindblom, Ulrik Lindforss
Summary: This study aimed to investigate whether gene mutations are an independent prognostic factor in colorectal cancer. Through immunohistochemistry or microsatellite instability testing, it was found that tumors with high gene mutations had lower distant recurrence rates within 6 years, but they were not associated with overall survival or relapse-free survival.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2023)
Article
Oncology
Nenad Kunac, Marina Degoricija, Jelena Viculin, Jasminka Omerovic, Janos Terzic, Katarina Vilovic, Jelena Korac-Prlic
Summary: This study demonstrates the potential of cGAS and STING as new therapeutic targets in microsatellite unstable colorectal cancer, particularly in the context of immune checkpoint inhibitors.
Letter
Oncology
Yana Debie, Timon Vandamme, Maria E. Goossens, Peter A. van Dam, Marc Peeters
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Otorhinolaryngology
Margot Baudelet, Frederic Duprez, Leen Van den Steen, Sandra Nuyts, Daan Nevens, Ann Goeleven, Caroline Vandenbruaene, Hanne Massonet, Alice Vergauwen, Heleen Bollen, Sarah Deschuymer, Kristien Wouters, Marc Peeters, Carl Van Laer, Steven Marien, Michiel Van den Brekel, Lisette van der Molen, Tom Vauterin, Joost van Dinther, Hilde Verstraete, Isabel Hutsebaut, Sabine Meersschout, Olivier Vanderveken, Marc De Bodt, Gwen Van Nuffelen
Summary: This multicenter RCT investigated the effect of three different service-delivery modes on patients' adherence to prophylactic swallowing exercises during radiotherapy. The study found that adherence decreased over time in all groups, but the therapist-supported group achieved the highest adherence rates. Increasing face-to-face contact with a speech-language therapist can overcome the problem of low adherence in this population.
Review
Oncology
Joe Ibrahim, Marc Peeters, Guy Van Camp, Ken Op de Beeck
Summary: The recent increase in cancer biomarker research has led to new insights in the field. Technological breakthroughs, such as long read sequencing and microarrays, have enabled high throughput profiling of biomarkers, while advances in bioinformatic tools have made reliable and accurate biomarkers a reality. These changes have renewed interest in biomarker research and provided opportunities for enhancing cancer management and early disease detection.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Genetics & Heredity
Mads Thomassen, Romy L. S. Mesman, Thomas V. O. Hansen, Mireia Menendez, Maria Rossing, Ada Esteban-Sanchez, Emma Tudini, Therese Torngren, Michael T. Parsons, Inge S. Pedersen, Soo H. Teo, Torben A. Kruse, Pal Moller, Ake Borg, Uffe B. Jensen, Lise L. Christensen, Christian F. Singer, Daniela Muhr, Marta Santamarina, Rita Brandao, Brage S. Andresen, Bing-Jian Feng, Daffodil Canson, Marcy E. Richardson, Rachid Karam, Tina Pesaran, Holly LaDuca, Blair R. Conner, Nelly Abualkheir, Lily Hoang, Fabienne M. G. R. Calleja, Lesley Andrews, Paul A. James, Dave Bunyan, Amanda Hamblett, Paolo Radice, David E. Goldgar, Logan C. Walker, Christoph Engel, Kathleen B. M. Claes, Eva Machackova, Diana Baralle, Alessandra Viel, Barbara Wappenschmidt, Conxi Lazaro, Ana Vega, Maaike P. G. Vreeswijk, Miguel de la Hoya, Amanda B. Spurdle
Summary: Skipping of BRCA2 exon 3 is a naturally occurring splicing event that complicates the clinical classification of related variants. This study used multiple evidence types to assess the pathogenicity of these variants and identified six loss-of-function mutations. The study also highlights the value of using a points-based approach for variant classification and the importance of considering cryptic splice site usage.
Article
Oncology
Yana Debie, Jonas R. M. Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Lise Verbruggen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Bart Peeters, Maria E. Goossens, Pieter Pannus, Kevin K. Arien, Sebastien Anguille, Annelies Janssens, Hans Prenen, Evelien L. J. Smits, Christof Vulsteke, Eva Lion, Marc Peeters, Peter A. van Dam
Summary: Patients with cancer have reduced humoral responses after double-dose COVID-19 vaccination, but their cellular response is comparable to healthy individuals. A third dose of BNT162b2 can boost immune responses in both healthy people and cancer patients. This study compares the effects of a third dose of BNT162b2 after homologous (double-dose BNT162b2) and heterologous (ChAdOx1) vaccination in cancer patients.
CLINICAL CANCER RESEARCH
(2023)
Letter
Oncology
Yana Debie, Peter A. van Dam, Maria E. Goossens, Marc Peeters, Timon Vandamme
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Katleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, Ken Op de Beeck, Guy Van Camp, Helena Oliveres, Hans Prenen, Timon Vandamme, Marc Peeters
Summary: One of the major challenges in digestive oncology is selecting the optimal therapy for RAS-mutated metastatic colorectal cancer (mCRC). Recent developments in targeting the RAS-pathway have shown promising results and may lead to clinical benefits for patients in the coming years. Although resistance remains a concern, strategic combination regimens have been developed to overcome this issue. In this review, we summarize the standard of care and discuss emerging therapies for RAS-mutated mCRC.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Marc Peeters, Hans-Peter Lipp, Minjeong Park, Ye Chan Yoon, Dirk Arnold
Summary: SB8 is a biosimilar of bevacizumab that has been extensively studied to demonstrate its similarity in various aspects. It is authorized for use in different types of tumors based on the concept of extrapolation. Additionally, SB8 offers the advantage of prolonged stability in diluted form compared to the reference bevacizumab. Although there are concerns about extrapolation, the "totality of evidence" supports the biosimilarity of SB8.
Article
Oncology
Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Summary: This study provides evidence that left-sided colorectal cancer has a significantly better prognosis compared to right-sided colorectal cancer, in all stages and ages combined. The survival of left-sided colorectal cancer is also longer than right-sided colorectal cancer in stage IV, regardless of MMR, RAS, and BRAF status.
Article
Microbiology
Baptiste Oosterlinck, Hannah Ceuleers, Wout Arras, Joris G. De Man, Karen Geboes, Heiko De Schepper, Marc Peeters, Sarah Lebeer, Jurgita Skieceviciene, Georgina L. Hold, Juozas Kupcinskas, Alexander Link, Benedicte Y. De Winter, Annemieke Smet
Summary: This study identified the mucin-microbiome signatures in gastric adenocarcinomas and their impact on clinical outcomes. The findings showed that intestinal mucin phenotype and high-level MUC13 expression were associated with poor survival, while gastric MUC5AC or MUC6 abundance was associated with a more favorable outcome. Furthermore, oral bacteria such as Neisseria, Prevotella, and Veillonella were found to play a potential role in MUC13 signaling and were associated with intestinal and mixed mucin phenotype tumors.
Article
Chemistry, Medicinal
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen, Christof Vulsteke
Summary: The lack of solid data and prospective studies has resulted in a lack of clear guidelines for cardiovascular monitoring in patients receiving immune checkpoint inhibitors (ICIs). In order to address this issue, we have initiated the CAVACI trial to investigate the short- and long-term cardiovascular effects of ICIs. Patient recruitment started in January 2022.
Article
Oncology
Valerie Desmedt, Aranzazu Jauregui-Amezaga, Liselotte Fierens, Sandrine Aspeslagh, Jeroen Dekervel, Els Wauters, Marc Peeters, Joao Sabino, Lara Crape, Michael Somers, Anne Hoorens, Joris Dutre, Triana Lobaton
Summary: This paper provides updated practice advice on the diagnosis and management of immune checkpoint inhibitor-induced gastrointestinal toxicity for gastroenterologists and oncologists. The use of immune checkpoint inhibitors in cancer immunotherapy has been shown to increase overall survival, but it also carries the risk of severe immune-mediated adverse events, particularly involving the gastrointestinal tract. The paper emphasizes the importance of early multidisciplinary approach and proposes criteria for diagnosis and treatment.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Microbiology
Estelle Meroc, Mark A. A. Fletcher, Germaine Hanquet, Mary P. E. Slack, Marc Baay, Kyla Hayford, Bradford D. D. Gessner, Lindsay R. R. Grant
Summary: Higher valency pneumococcal conjugate vaccines (PCV15 and PCV20) have been developed to tackle the disease burden caused by non-vaccine serotypes. This review provides an overview of the epidemiological characteristics of serotypes beyond PCV13, analyzing their association with different diseases and their antimicrobial non-susceptibility. The findings can contribute to informed decision-making regarding the choice and use of higher valency PCVs.
Review
Oncology
Laura Marien, Odeta Islam, Siddharth Chhajlani, Willem Lybaert, Marc Peeters, Guy Van Camp, Ken Op de Beeck, Timon Vandamme
Summary: Given the considerable heterogeneity in neuroendocrine neoplasms, there is a need for multiple biomarkers to capture different aspects of these tumors. Circulating biomarkers, such as NETest and ctDNA-based analysis, show promise in enhancing accuracy of diagnosis, prognosis determination, and therapy prediction and monitoring.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Summary: This study confirms that left-sided colorectal cancer has a better prognosis compared to right-sided colorectal cancer in the Belgian population. The presence of biomarkers such as MMR, BRAF, and RAS status does not significantly affect the prognostic effect of primary tumor location.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
